Tradestie Institutional Equity Comparison Engine

QTTB vs RADX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

QTTB Overall Edge

QTTB Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Q32 Bio Inc. Common Stock (QTTB) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, QTTB trades at N/M Forward P/E with 34.2% operating margin (+0.0% YoY revenue) versus RADX at N/M Forward P/E and -411.6% operating margin (-36.9% YoY). In options structure, QTTB sits in BREAKDOWN (42nd %ile IV; Dealer Gamma Walls on Pro) against RADX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner QTTB
QTTB N/M vs RADX N/M Fwd P/E
Growth & Margin Winner QTTB
Op Margin 34.2% vs -411.6% ยท YoY +0.0% vs -36.9%
Momentum & Technical Winner QTTB
1Y +293.4% vs -86.0% ยท 52W Pos 30% vs 0%
Options & Structure Winner QTTB
BREAKDOWN (42nd %ile IV) vs UNCLASSIFIED (N/A IV)
QTTB NASDAQ
Q32 Bio Inc. Common Stock
Pharmaceutical Preparations
$8.34
-1.65% 1D
Market Cap $253.8M
1M Return -5.23%
1Y Return +293.4%
Forward P/E N/M
Unified AI Score
40.8 / 100 SELL
Tech 23.0 Fund 54.0 Flow 71.0 Mom 50.0
RADX NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap $10.6M
1M Return -33.64%
1Y Return -86.04%
Forward P/E N/M
Unified AI Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: QTTB +293.4% RADX -86.04% Spread: +379.75 pp (QTTB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
QTTB TTM Op. Margin: 34.2% RADX TTM Op. Margin: -411.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QTTB vs RADX. Trailing 12-month operating profitability (QTTB 34.2% vs RADX -411.6%) and valuation multiples (QTTB N/M vs RADX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: QTTB (8) vs RADX (1)
Institutional Metric QTTB RADX Criterion Row Winner
Market Capitalization Scale $253.8M $10.6M Larger Scale QTTB
Trailing P/E Ratio Valuation 2.4x N/M Lower Multiple QTTB
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -36.9% Higher Growth QTTB
Operating Margin (TTM) Profitability 34.2% -411.6% Higher Margin QTTB
Net Profit Margin Profitability 60.0% 0.0% Higher Margin QTTB
Return on Equity (ROE) Capital Efficiency 24.0% -174.7% Higher ROE QTTB
52-Week Range Position Momentum 30% ($2โ€“$24) 0% ($1โ€“$16) Stronger Trend QTTB
Beta / 30D Volatility Risk Regime 0.02ฮฒ ยท 40% Vol 0.52ฮฒ ยท 109% Vol Lower Realized Risk QTTB
Unified Institutional Score Composite Signal 40.8 / 100 (SELL) 41.1 / 100 (SELL) Higher Composite RADX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full QTTB vs RADX Buy Guide
QTTB BREAKDOWN
93d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 42nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live QTTB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RADX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RADX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither QTTB nor RADX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.